je.st
news
FDA Advisory Committee Recommends Approval Of BREO ELLIPTA For The Treatment Of COPD
2013-05-01 06:23:30| drugdiscoveryonline News Articles
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO™ ELLIPTA™ as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against)
Tags: of
treatment
committee
approval
Category:Biotechnology and Pharmaceuticals